Table 4. Safety and efficacy endpoints.
| Variables | Overall population (N=62 patients) | |
|---|---|---|
| 30-day safety endpoint | 0 (0) | |
| Coronary dissection >NHLBI type D | 0 (0) | |
| Perforation | 0 (0) | |
| Decrease of TIMI flow (<2) | 0 (0) | |
| Acute occlusion | 0 (0) | |
| Visible thrombus formation | 0 (0) | |
| Significant air embolus | 0 (0) | |
| Relation to procedure | 0 (0) | |
| Relation to robot | 0 (0) | |
| MACE | 0 (0) | |
| Efficacy endpoint | Procedural technical success | 59 (95.2) |
| Total manual conversion | 3 (4.8) | |
| Data are n (%). MACE: major adverse cardiac event; NHLBI: National Heart, Lung, and Blood Institute; TIMI: Thrombolysis In Myocardial Infarction | ||